Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Summary

The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).

Timeline

Start

2019-04-03

Primary completion

2024-08-29

Completion

2024-08-29

Outcome

Outcome not reported

Stopped (Business): “Study stopped due to strategic reasons. The decision is not based on specific safety findings as the safety observed in the phase II part of the study is in line with what was reported in the phase I part.”

Drugs

Indications